NanJing Pharmaceutical (600713.SS) Earnings Analysis
NanJing Pharmaceutical (600713.SS) has no confirmed upcoming earnings date. Trailing P/E 10.34.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600713.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 600713.SS. This page updates as the calendar is published.
600713.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-05-30 | 0.08671 CNY | n/a | n/a | n/a |
| 2025-03-31 | 0.135 CNY | n/a | n/a | n/a |
| 2024-12-31 | 0.09881 CNY | n/a | n/a | n/a |
| 2024-09-28 | 0.1006 CNY | n/a | n/a | n/a |
600713.SS valuation and analyst view
| Trailing P/E | 10.34 |
|---|---|
| Trailing EPS | 0.48461 CNY |
| Price / book | 0.87 |
| Dividend yield | 3.39% |
| Market cap | 6.48B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is NanJing Pharmaceutical (600713.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 600713.SS. This page updates as the calendar is published.
Did 600713.SS beat earnings last quarter?
Consensus estimate data was not available for 600713.SS's 2025-05-30 report.
What is 600713.SS's current P/E ratio and EPS?
600713.SS trades at a trailing P/E of 10.34 on trailing EPS of 0.48460849162753866 CNY.
What do analysts rate 600713.SS?
600713.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.